Forrester’s Technology & Security Predictions 2025: Tech Leaders Will Triple The Adoption Of AIOps To Reduce Technical Debt
22.10.2024 16:23:00 CEST | Business Wire | Press Release
According to Forrester’s (Nasdaq: FORR) 2025 technology and security predictions, 75% of technology decision-makers will see their technical debt rise to a moderate or high level of severity by 2026. This will be due to the rapid development of AI solutions, which are adding complexity to IT landscapes.
To stem the tsunami of technical debt, in 2025, tech leaders will triple the adoption of AI for IT operations (AIOps) platforms, which deliver contextually aware data to enhance human judgment, automatically remediate incidents, and improve business outcomes. While AIOps is the future, IT leaders aiming to run a high-performance IT organization will also need to invest in building the right culture, data, architecture, and security practices to accelerate business growth.
Forrester’s technology and security predictions analyze the dynamics and emerging trends to watch for in the year ahead. These insights help leaders and their teams prepare for future challenges and take advantage of new opportunities to thrive in 2025. Topics include: artificial intelligence; automation; tech leadership; cloud computing; tech infrastructure and operations; enterprise software; software development; and cybersecurity, risk, and privacy.
Highlights from Forrester’s 2025 technology and security predictions include the following:
- Private cloud will gain momentum with VMWare alternatives.In 2025, most major public cloud providers will increase investments in private cloud, but it’s unlikely that newcomers will increase business with dominant private cloud player VMware given recent bundling and pricing changes.
- Most enterprises fixated on AI ROI will scale back prematurely. Leaders are realizing that ROI from AI investments will take longer than they anticipated. Impatience with AI ROI could prompt enterprises to prematurely scale back investments, which would be a long-term disadvantage.
- The European Union will fine a generative AI provider for the first time under the EU AI Act. With the EU AI Office and data protection authorities joining forces, a general-purpose AI (GPAI) model’s provider will receive the first fine for violating the EU AI Act in 2025. As with the General Data Protection Regulation, the EU AI Act applies to entities that operate in the EU as well as those that supply AI systems or GPAI models to the EU, regardless of where they’re headquartered.
“In 2024, technology and security leaders ran pilots across their enterprises to explore innovative applications of AI,” said Sharyn Leaver, chief research officer at Forrester, “but not all AI initiatives yielded the intended business outcomes. While this bold experimentation will continue in 2025, leaders will also focus heavily on putting the lessons learned into practice to ensure that their investments deliver true business value.”
Resources:
- Download Forrester’s 2025 Predictions guides for technology and security leaders, B2C marketing and customer experience leaders, and B2B marketing and sales leaders.
- Register to attend Forrester’s webinar covering key technology and security predictions for the coming year.
- Learn more about Forrester’s 2025 predictions.
- Visit Forrester’s 2025 Predictions hub to access additional complimentary resources.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the center of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; and the shared wisdom of our clients.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241022193804/en/
Contacts
Press:
Hannah Segvich
hsegvich@forrester.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom